Legato Capital Management LLC Has $1.14 Million Holdings in Repligen Co. (NASDAQ:RGEN)

Legato Capital Management LLC decreased its position in shares of Repligen Co. (NASDAQ:RGEN) by 31.4% in the fourth quarter, Holdings Channel reports. The fund owned 7,940 shares of the biotechnology company’s stock after selling 3,630 shares during the period. Legato Capital Management LLC’s holdings in Repligen were worth $1,143,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of RGEN. UMB Bank n.a. boosted its stake in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. grew its stake in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares during the last quarter. Resources Management Corp CT ADV bought a new position in Repligen during the third quarter worth $37,000. Quarry LP raised its stake in Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 239 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in Repligen in the 3rd quarter valued at $45,000. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Down 2.5 %

NASDAQ RGEN opened at $145.72 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The stock has a market capitalization of $8.16 billion, a P/E ratio of -393.83, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The stock has a fifty day moving average of $155.45 and a 200-day moving average of $149.14.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period last year, the company earned $0.23 earnings per share. The company’s revenue was up 9.7% on a year-over-year basis. On average, equities research analysts forecast that Repligen Co. will post 1.54 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on RGEN shares. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. HC Wainwright reduced their price objective on Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Wolfe Research assumed coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Canaccord Genuity Group initiated coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus target price of $186.00.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.